CytoAgents

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products to treat life-threatening symptoms associated with Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The company's mission is to address the 'cytokine storm,' a common and potentially lethal overreaction of the immune system that occurs in response to advanced immunotherapies, viral infections, and autoimmune conditions. The company's lead candidate, CTO1681 (formerly GP1681), is a novel, orally bioavailable small molecule designed to modulate the body's natural immune response. Unlike traditional steroids or broad immunosuppressants, CTO1681 targets the NF-kB and PGE2 signaling pathways to downregulate cytokine production while leaving the immune system functionally intact. This approach is intended to preserve the anti-cancer efficacy of therapies like CAR T-cells and bispecific antibodies while mitigating their toxic side effects.